WO2015065524A3 - Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas - Google Patents

Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas Download PDF

Info

Publication number
WO2015065524A3
WO2015065524A3 PCT/US2014/038993 US2014038993W WO2015065524A3 WO 2015065524 A3 WO2015065524 A3 WO 2015065524A3 US 2014038993 W US2014038993 W US 2014038993W WO 2015065524 A3 WO2015065524 A3 WO 2015065524A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
differentiation
clustering
suspension
pluripotent stem
Prior art date
Application number
PCT/US2014/038993
Other languages
English (en)
Other versions
WO2015065524A2 (fr
Inventor
Benjamin Fryer
Daina LANIAUSKAS
Marcia BLACKMOORE
Haiyun Wang
Kostadinka LILOVA
Shelley Nelson
Elizabeth ROSOCHA
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/998,974 external-priority patent/US10377989B2/en
Priority to CN201480059910.5A priority Critical patent/CN105793413A/zh
Priority to KR1020187034291A priority patent/KR20180128529A/ko
Priority to JP2016527338A priority patent/JP2016534731A/ja
Priority to CA2928639A priority patent/CA2928639A1/fr
Priority to AU2014342995A priority patent/AU2014342995C1/en
Priority to KR1020167014409A priority patent/KR20160079072A/ko
Priority to MX2016005657A priority patent/MX2016005657A/es
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Priority to EP14857034.4A priority patent/EP3063268A4/fr
Priority to RU2016121409A priority patent/RU2689710C2/ru
Priority to SG11201603045VA priority patent/SG11201603045VA/en
Publication of WO2015065524A2 publication Critical patent/WO2015065524A2/fr
Publication of WO2015065524A3 publication Critical patent/WO2015065524A3/fr
Priority to PH12016500782A priority patent/PH12016500782A1/en
Priority to AU2018208707A priority patent/AU2018208707A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/19—Growth and differentiation factors [GDF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes de préparation de groupes de cellules souches pluripotentes agrégés aux fins de différenciation. L'invention concerne en particulier des méthodes de différenciation de cellules souches pluripotentes en lignées de cellules béta, de cellules cardiaques et de cellules neuronales par regroupement en suspension. Les méthodes comprennent la préparation des groupes de cellules agrégés puis de la différenciation de ces agrégats.
PCT/US2014/038993 2013-11-01 2014-05-21 Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas WO2015065524A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SG11201603045VA SG11201603045VA (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
MX2016005657A MX2016005657A (es) 2013-11-01 2014-05-21 Suspensión y agrupamiento de células madre humanas pluripotentes para la diferenciación a células endocrinas pancreáticas.
JP2016527338A JP2016534731A (ja) 2013-11-01 2014-05-21 膵内分泌細胞への分化のためのヒト多能性幹細胞の懸濁及び集団化
CA2928639A CA2928639A1 (fr) 2013-11-01 2014-05-21 Mise en suspension et agregation de cellules souches pluripotentes humaines aux fins de differenciation en cellules endocrines du pancreas
AU2014342995A AU2014342995C1 (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
KR1020167014409A KR20160079072A (ko) 2013-11-01 2014-05-21 췌장 내분비 세포로의 분화를 위한 인간 만능 줄기세포의 현탁 및 클러스터링
EP14857034.4A EP3063268A4 (fr) 2013-11-01 2014-05-21 Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas
CN201480059910.5A CN105793413A (zh) 2013-11-01 2014-05-21 用于分化成胰腺内分泌细胞的人多能干细胞的悬浮和群集
KR1020187034291A KR20180128529A (ko) 2013-11-01 2014-05-21 췌장 내분비 세포로의 분화를 위한 인간 만능 줄기세포의 현탁 및 클러스터링
RU2016121409A RU2689710C2 (ru) 2013-11-01 2014-05-21 Суспендирование и кластеризация плюрипотентных стволовых клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
PH12016500782A PH12016500782A1 (en) 2013-11-01 2016-04-27 Suspension and clustering of human pluripotent stem cells for differentation into pancreatic endocrine cells
AU2018208707A AU2018208707A1 (en) 2013-11-01 2018-07-26 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361962158P 2013-11-01 2013-11-01
US61/962,158 2013-11-01
US13/998,974 US10377989B2 (en) 2012-12-31 2013-12-30 Methods for suspension cultures of human pluripotent stem cells
US13/998,974 2013-12-30

Publications (2)

Publication Number Publication Date
WO2015065524A2 WO2015065524A2 (fr) 2015-05-07
WO2015065524A3 true WO2015065524A3 (fr) 2015-08-13

Family

ID=53004904

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2014/038993 WO2015065524A2 (fr) 2013-11-01 2014-05-21 Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas
PCT/US2014/042796 WO2015065537A1 (fr) 2013-11-01 2014-06-17 Mise en suspension et regroupement de cellules souches pluripotentes humaines pour la différenciation en cellules endocrines pancréatiques

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2014/042796 WO2015065537A1 (fr) 2013-11-01 2014-06-17 Mise en suspension et regroupement de cellules souches pluripotentes humaines pour la différenciation en cellules endocrines pancréatiques

Country Status (12)

Country Link
EP (2) EP3063268A4 (fr)
JP (2) JP2016534731A (fr)
KR (4) KR20160079072A (fr)
CN (2) CN105793413A (fr)
AU (4) AU2014342995C1 (fr)
BR (1) BR112016009393A8 (fr)
CA (2) CA2928639A1 (fr)
MX (2) MX2016005657A (fr)
PH (2) PH12016500783A1 (fr)
RU (2) RU2689710C2 (fr)
SG (2) SG11201603045VA (fr)
WO (2) WO2015065524A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160079072A (ko) * 2013-11-01 2016-07-05 얀센 바이오테크 인코포레이티드 췌장 내분비 세포로의 분화를 위한 인간 만능 줄기세포의 현탁 및 클러스터링
WO2017223233A1 (fr) * 2016-06-23 2017-12-28 Tithon Biotech, Inc. Cellules exprimant le récepteur d'hormone parathyroïde 1 et leurs utilisations
SG11201903428XA (en) * 2016-11-16 2019-05-30 Cynata Therapeutics Ltd Pluripotent stem cell assay
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
EP3654996A4 (fr) * 2017-07-21 2021-03-24 Semma Therapeutics, Inc. Réagrégation de cellules bêta pancréatiques dérivées de cellules souches
JP7000896B2 (ja) * 2017-08-23 2022-01-19 王子ホールディングス株式会社 細胞シート形成部材、細胞シート形成部材の製造方法、および、細胞シートの製造方法
AU2019205942A1 (en) * 2018-01-05 2020-08-13 Platelet Biogenesis, Inc. Compositions and methods for producing megakaryocytes
JP2021510527A (ja) * 2018-01-18 2021-04-30 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 懸濁培養におけるヒト多能性幹細胞系の分化のための方法
KR102115360B1 (ko) * 2018-05-30 2020-05-26 주식회사 바이블리오테카 성체 줄기세포 배양액 및 그 제조방법
US20200080107A1 (en) 2018-09-07 2020-03-12 Crispr Therapeutics Ag Universal donor cells
WO2020243668A1 (fr) 2019-05-31 2020-12-03 W. L. Gore & Associates, Inc. Dispositifs d'encapsulation de cellules présentant des distances de diffusion d'oxygène régulées
JP2022534545A (ja) 2019-05-31 2022-08-01 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティド 生体適合性メンブレン複合体
EP3975926A1 (fr) 2019-05-31 2022-04-06 W.L. Gore & Associates, Inc. Composite à membrane biocompatible
CA3139591C (fr) 2019-05-31 2024-01-16 Timothy M. BRUHN Composite a membrane biocompatible
CN114364791A (zh) 2019-09-05 2022-04-15 克里斯珀医疗股份公司 通用供体细胞
US11104918B2 (en) 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells
CN114729323A (zh) * 2019-11-22 2022-07-08 诺和诺德股份有限公司 旋转聚集的神经微球及其应用
CA3203392A1 (fr) 2020-12-31 2022-07-07 Alireza Rezania Cellules donneuses universelles
WO2022203051A1 (fr) * 2021-03-25 2022-09-29 株式会社カネカ Procédé de production d'une population de cellules souches pluripotentes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US20130189777A1 (en) * 2011-12-22 2013-07-25 Janssen Biotech, Inc. Differentiation of Human Embryonic Stem Cells into Single Hormonal Insulin Positive Cells
US20130224156A1 (en) * 2012-02-29 2013-08-29 Riken Method of producing human retinal pigment epithelial cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533480A (ja) * 2001-11-09 2005-11-10 アーテセル・サイエンシズ・インコーポレーテツド 脂肪組織由来間質細胞の膵内分泌分化およびその使用
DK2733203T3 (en) * 2006-08-02 2019-02-04 Technion Res & Dev Foundation PROCEDURES FOR EXPANSION OF EMBRYONAL STEM CELLS IN A SUSPENSION CULTURE
WO2008056779A1 (fr) * 2006-11-09 2008-05-15 Japan As Represented By The President Of International Medical Center Of Japan Procédé destiné à la culture et au passage d'une cellule souche embryonnaire de primate, et procédé destiné à induire la différenciation de la cellule souche embryonnaire
EP2559756B1 (fr) * 2007-07-01 2019-12-18 Janssen Biotech, Inc. Culture de cellules souches pluripotentes uniques
GB0800524D0 (en) * 2008-01-14 2008-02-20 Univ Brighton Cell culture system
WO2009116951A2 (fr) * 2008-03-17 2009-09-24 Agency For Science, Technology And Research Microsupports pour culture de cellules-souches
EP2310492B1 (fr) * 2008-06-30 2015-07-22 Janssen Biotech, Inc. Différenciation de cellules souches pluripotentes
US8008075B2 (en) * 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
US8895300B2 (en) * 2008-11-04 2014-11-25 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
EP2464723B1 (fr) * 2009-08-12 2016-06-22 Kyoto University Procédé d'induction d'une différenciation de cellules souches pluripotentes en cellules précurseurs neurales
US8932857B2 (en) * 2010-06-15 2015-01-13 Kyoto University Method for selecting reduced differentiation resistance human induced pluripotent stem cells
US9085757B2 (en) * 2010-06-17 2015-07-21 Regents Of The University Of Minnesota Production of insulin producing cells
PL2611910T3 (pl) * 2010-08-31 2018-06-29 Janssen Biotech, Inc Różnicowanie ludzkich embrionalnych komórek macierzystych
WO2012117333A1 (fr) * 2011-02-28 2012-09-07 Stempeutics Research Malaysia Sdn Bhd Isolement et expansion de cellules souches adultes, composition thérapeutique les comprenant et utilisations associées
WO2013056072A1 (fr) * 2011-10-13 2013-04-18 Wisconsin Alumni Research Foundation Génération de cardiomyocytes à partir de cellules souches pluripotentes humaines
MX2015008619A (es) * 2012-12-31 2016-01-12 Janssen Biotech Inc Suspension y agrupamiento de celulas humanas pluripotentes para la diferenciacion a celulas endocrinas pancreaticas.
KR20160079072A (ko) * 2013-11-01 2016-07-05 얀센 바이오테크 인코포레이티드 췌장 내분비 세포로의 분화를 위한 인간 만능 줄기세포의 현탁 및 클러스터링

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US20130189777A1 (en) * 2011-12-22 2013-07-25 Janssen Biotech, Inc. Differentiation of Human Embryonic Stem Cells into Single Hormonal Insulin Positive Cells
US20130224156A1 (en) * 2012-02-29 2013-08-29 Riken Method of producing human retinal pigment epithelial cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
EGUIZABAL ET AL.: "Complete Meiosis from Human Induced Pluripotent Stem Cells.", STEM CELLS., vol. 29, no. 8, 2011, pages 1186 - 95, XP055218519 *
MINAMI ET AL.: "A Small Molecule that Promotes Cardiac Differentiation of Human Pluripotent Stem Cells under Defined, Cytokine- and Xeno-free Conditions.", CELL REP., vol. 2, no. 5, November 2012 (2012-11-01), pages 1448 - 60., XP055097336 *
NIE ET AL.: "Scalable passaging of adherent human pluripotent stem cells.", PLOS ONE., vol. 9, no. 1, 2014, pages E88012, XP055218521 *
ROWLEY ET AL.: "Meeting Lot-Size Challenges of Manufacturing Adherent Cells for Therapy.", BIOPROCESS INT., vol. 10, no. 3, March 2012 (2012-03-01), pages 16 - 22, XP055218518 *
STACPOOLE ET AL.: "Efficient derivation of neural precursor cells, spinal motor neurons and midbrain dopaminergic neurons from human ES cells at 3% oxygen.", NAT PROTOC., vol. 6, no. 8, 2011, pages 1229 - 40, XP055218516 *
VIEIRA ET AL.: "Modulation of neuronal stem cell differentiation by hypoxia and reactive oxygen species.", PROG NEUROBIOL., vol. 93, no. 3, 2011, pages 444 - 55, XP028175304 *
WANT ET AL.: "The larger scale expansion of pluripotent stem cells for regenerative medicine purposes.", LOUGHBOROUGH UNIVERSITY INSTITUTIONAL REPOSITORY, SUBMITTED FOR PUBLICATION ON REGEN MED., vol. 7, no. 1, January 2012 (2012-01-01), pages 71 - 84, XP055354028, Retrieved from the Internet <URL:https://dspace.boro.ac.uk/dspace- jspui/bitstream/2134/11041/6/HewittVersion.pdf> [retrieved on 20140826] *
YANG ET AL.: "Evaluation of human MSCs cell cycle, viability and differentiation in micromass culture.", BIORHEOLOGY., vol. 43, no. 3-4, 2006, pages 489 - 96, XP055339090, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/16912420> [retrieved on 20140917] *
ZUSCIK ET AL.: "Regulation of chondrogenesis and chondrocyte differentiation by stress.", J CLIN INVEST., vol. 118, no. 2, 2008, pages 429 - 38, XP055218520 *

Also Published As

Publication number Publication date
RU2016121409A (ru) 2017-12-04
MX2016005657A (es) 2017-01-05
KR20160079072A (ko) 2016-07-05
RU2016121404A (ru) 2017-12-04
AU2014343007A1 (en) 2016-05-05
PH12016500783A1 (en) 2016-06-13
RU2016121409A3 (fr) 2018-03-29
SG11201603045VA (en) 2016-05-30
CA2928639A1 (fr) 2015-05-07
AU2014342995A1 (en) 2016-05-05
WO2015065524A2 (fr) 2015-05-07
CN105683362A (zh) 2016-06-15
AU2014342995C1 (en) 2018-08-09
RU2016121404A3 (fr) 2018-03-29
AU2014343007B2 (en) 2018-04-26
SG11201603047PA (en) 2016-05-30
PH12016500782A1 (en) 2016-06-13
MX2016005658A (es) 2017-01-05
AU2014343007C1 (en) 2018-08-09
CA2928741A1 (fr) 2015-05-07
AU2018208717A1 (en) 2018-08-16
AU2014342995B2 (en) 2018-04-26
CN105793413A (zh) 2016-07-20
JP2017500013A (ja) 2017-01-05
EP3063268A4 (fr) 2017-11-29
KR20180128529A (ko) 2018-12-03
KR20160079071A (ko) 2016-07-05
BR112016009393A8 (pt) 2020-03-24
KR20180130001A (ko) 2018-12-05
RU2689710C2 (ru) 2019-05-29
EP3063269A4 (fr) 2017-07-12
EP3063268A2 (fr) 2016-09-07
WO2015065537A1 (fr) 2015-05-07
AU2018208707A1 (en) 2018-08-16
EP3063269A1 (fr) 2016-09-07
JP2016534731A (ja) 2016-11-10

Similar Documents

Publication Publication Date Title
WO2015065524A3 (fr) Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas
IL285922A (en) Interneuronal cells of the cerebral cortex and other neurons produced by direct differentiation of pluripotent and multipotent cells
PH12018501294A1 (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
PH12015501477A1 (en) Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
WO2014124087A8 (fr) Cellules progénitrices d&#39;oligodendrocyte issues de cellules pluripotentes induites pour le traitement de troubles de la myéline
WO2014100779A8 (fr) Procédés de production de plaquettes à partir de cellules souches pluripotentes, et compositions associées
EP3633026A4 (fr) Méthode pour induire la différenciation d&#39;une cellule mésodermique intermédiaire en une cellule progénitrice rénale, et méthode pour induire la différenciation d&#39;une cellule souche pluripotente en une cellule progénitrice rénale
WO2012030539A3 (fr) Différenciation de cellules souches embryonnaires humaines
WO2014153069A3 (fr) Compositions et procédés de reprogrammation de lignées de cellules souches hématopoïétiques
CA2860107C (fr) Differenciation de cellules souches embryonnaires humaines en cellules positives pour l&#39;insuline hormonales individuelles
PH12014501426A1 (en) Induced pluripotent stem cells from human umbilical cord tissue-derived cells
PH12014502686A1 (en) Differentiation of human embryonic stem cells into pancreatic endoderm
WO2016061071A8 (fr) Generation de keratinocytes a partir de cellules souches pluripotentes et entretien de cultures de keratinocytes
MY184796A (en) Method for manufacturing ciliary marginal zone-like structure
EP2504425A4 (fr) Différenciation de cellules souches embryonnaires humaines et de cellules souches pluripotentes induites
WO2012092049A8 (fr) Modification des adipocytes bruns
EP3464569A4 (fr) Procédés in vitro de différenciation de cellules souches en neurones et neurones générés utilisant lesdits procédés in vitro de différenciation de cellules souches en neurones
MX2015017330A (es) Metodo para la diferenciacion de celulas madre pluripotenciales en precursores renales multi-competentes.
WO2014113704A3 (fr) Amélioration de la différenciation de cellules souches mésenchymateuses
MX2016014008A (es) Metodo para diferenciacion de celulas madre pluripotentes en cardiomiocitos.
WO2011159050A3 (fr) Procédé pour différencier des cellules progénitrices neurales humaines en neurones dopaminergiques, et milieu pour la différenciation de celles-ci
EP3652200A4 (fr) Induction de cellules progénitrices neurales, de cellules progénitrices d&#39;oligodendrocytes et d&#39;oligodendrocytes par différenciation de cellules souches à l&#39;aide de facteurs de transcription de points de repère
PH12014501383A1 (en) Induced pluripotent stem cells prepared from human kidney-derived cells
WO2015089228A3 (fr) Compositions et procédés pour produire et gérer des adipocytes bruns
KR101896803B9 (ko) 인간 만능줄기세포로부터 중간엽 줄기세포로의 분화 유도 생산율을 증가시키는 방법 및 이에 의해 생성된 중간엽 줄기세포

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2928639

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12016500782

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2016527338

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/005657

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014342995

Country of ref document: AU

Date of ref document: 20140521

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016009399

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: IDP00201603594

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 20167014409

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016121409

Country of ref document: RU

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014857034

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014857034

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14857034

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112016009399

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160427